tlc599
Osteoarthritis of the Knee
Taiwan Liposome CompanySmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Osteoarthritis of the Knee cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Eli Lilly and Company | Phase 3 | BB |
Buprenorphine Purdue Pharma LP | Phase 3 | B |
DEXAMETHASONE Taiwan Liposome Company | Phase 3 | B |
Naproxen Astellas Pharma Europe B.V. | Phase 2 | B |
Nktr-181 Nektar Therapeutics | Phase 2 | B |
View all 9 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →